# A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies

> **NCT06388902** · PHASE1 · SUSPENDED · sponsor: **BioRay Pharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **DRUG:** BR115 for injection

## Key facts

- **NCT ID:** NCT06388902
- **Lead sponsor:** BioRay Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-02-19
- **Primary completion:** 2028-08
- **Final completion:** 2028-12
- **Target enrollment:** 120 (ESTIMATED)
- **Why stopped:** Due to drug stability and global interests, it is currently in a suspended state.
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388902, "A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06388902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*